Baxalta (Baxter) Opening New Facility in Massachusetts
September 30, 2014; Posted by: WeBleed staff
Baxter spin-off, Baxalta, set to open new facility in mid-2015.
Industry news out of Chicago today in the field of bleeding disorders. According to an article by Kristen Schorsch of Crain’s Chicago Business, Baxter International has announced plans to open a 200,000-square-foot research and development facility in Cambridge, Massachusetts, for Baxalta, their biopharmaceuticals business spin off. Ludwig Hantson, who will be CEO of the new Baxalta Inc. beginning in mid-2015 had the following statement to say on the new facility:
“Critical elements to our success as an independent biopharmaceuticals company will be our ability to accelerate innovation, optimize R&D productivity and deliver on our promise to patients. Joining this unmatched biotech community is an important step.”
Over 400 research and development positions will be moving to Cambridge next year. At the moment, these employees are based in California and Europe. Earlier in March, Baxter made the announcement to split the $15 billion company in two: one for developing and marketing biopharmaceuticals and one for medical products. The biopharmaceuticals business includes treatments for hemophilia and other bleeding disorders as well as blood plasma therapies used to treat immune deficiencies and other problems.
Photo Credit – Baxter International/Chicago Tribune
webleed.org – your source for bleeding news!
